Thermo Fisher to Sell Microbiology Business to Astorg for About $1.075 Billion
By Colin Kellaher
Thermo Fisher Scientific has struck a deal to sell its microbiology business to European private-equity firm Astorg for about $1.075 billion.
Thermo Fisher on Monday said the microbiology business, which provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food-safety testing, generated $645 million in revenue last year.
Waltham, Mass., life-sciences giant Thermo Fisher posted 2025 revenue of nearly $44.6 billion.
Thermo Fisher said it expects to complete the sale, which includes cash and a $50 million seller note, in the second half of the year, adding that it expects the divestiture will clip adjusted per-share earnings by 15 cents in its first full year.
Astorg, which specializes in healthcare, technology and business-services investments, has more than $28 billion in assets under management.
The firm was part of a group that sold endpoint data solutions provider Clario Holdings to Thermo Fisher for nearly $8.9 billion in a deal that closed in March.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 27, 2026 08:52 ET (12:52 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States